STAA vs. RXST, WRBY, EYE, BLCO, ZLAB, KYMR, PRVA, ARVN, TDOC, and RCKT Should you be buying STAAR Surgical stock or one of its competitors? The main competitors of STAAR Surgical include RxSight (RXST), Warby Parker (WRBY), National Vision (EYE), Bausch + Lomb (BLCO), Zai Lab (ZLAB), Kymera Therapeutics (KYMR), Privia Health Group (PRVA), Arvinas (ARVN), Teladoc Health (TDOC), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "medical" sector.
STAAR Surgical (NASDAQ:STAA ) and RxSight (NASDAQ:RXST ) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, community ranking, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.
STAAR Surgical has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.
96.7% of STAAR Surgical shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 1.0% of STAAR Surgical shares are held by company insiders. Comparatively, 21.1% of RxSight shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, RxSight had 4 more articles in the media than STAAR Surgical. MarketBeat recorded 7 mentions for RxSight and 3 mentions for STAAR Surgical. RxSight's average media sentiment score of 1.03 beat STAAR Surgical's score of 0.40 indicating that RxSight is being referred to more favorably in the news media.
STAAR Surgical received 249 more outperform votes than RxSight when rated by MarketBeat users. However, 66.67% of users gave RxSight an outperform vote while only 56.10% of users gave STAAR Surgical an outperform vote.
STAAR Surgical has a net margin of 4.69% compared to RxSight's net margin of -44.01%. STAAR Surgical's return on equity of 6.83% beat RxSight's return on equity.
STAAR Surgical currently has a consensus price target of $47.13, indicating a potential upside of 10.36%. RxSight has a consensus price target of $60.63, indicating a potential downside of 0.04%. Given STAAR Surgical's higher probable upside, equities analysts plainly believe STAAR Surgical is more favorable than RxSight.
STAAR Surgical has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.
Summary STAAR Surgical beats RxSight on 10 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding STAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
STAAR Surgical Competitors List
Related Companies and Tools
